The fatty acid synthase (FASN or FAS) levels and the de novo synthesis of fatty acids are upregulated in several malignancies, such as breast [3], gastric [4], lung [5], liver [6], prostate [7,8], pancreatic [9], esophageal [10], and ovarian cancers [11], to maintain the uncontrolled growth and the increased survival rate of cancer cells. This evidence concerns the gene FASN and ovarian cancer.